在心力衰竭中使用芬 - - 一种新的治疗方法
Amalie Holst-Hansen1, Daniela Grimm1,2, Markus Wehland2
1Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.
International journal of molecular sciences
|January 8, 2025
概括
芬瑞是一种新型药物,有效降低心力衰竭患者的炎症和纤维化,特别是2型糖尿病和慢性病患者. 临床研究表明,它有可能改善这些高风险人群的心血管结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一种复杂的综合征,会损害心脏的功能.
- 高血压与各种风险因素有关,包括高血压,2型糖尿病 (T2DM) 和慢性病 (CKD).
- 慢性病通过系统性炎症加剧HF,影响心血管系统.
研究的目的:
- 审查芬在治疗心力衰竭中的作用.
- 讨论支持菲内伦在HF患者中的疗效的临床证据.
- 为了突出菲内伦在患有同时存在CKD和T2DM的患者中的好处.
主要方法:
- 关于芬的临床研究的综述.
- 分析作为非类固醇矿物质皮质体受体对手的芬瑞的作用机制.
- 评估费内伦的安全性和疗效,包括组织分布和受体选择性.
主要成果:
- 芬瑞能有效降低心脏和纤维化和炎症.
- 临床试验表明,用finerenone治疗的CKD和T2DM患者的心血管结局减少.
- 费内伦对矿物质皮质类受体具有很高的亲和力和选择性,具有较低的副作用风险,如高血症.
结论:
- 菲内伦是一种有前途的治疗心力衰竭的药物,特别是在T2DM和CKD患者中.
- 它的抗炎和抗纤维性质为心血管提供了显著的益处.
- 进一步的研究是有必要的,以探索finerenone的全部治疗潜力,包括组合疗法.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:26Heart Failure Drugs: Inotropic Agents
515
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515
01:33Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K